ArticleFrontiers in cardiovascular medicine2026
Growth differentiation factor 15 level changes in the early and late periods after radiofrequency and pulsed field catheter ablation of atrial fibrillation.
Article in Frontiers in cardiovascular medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Growth differentiation factor 15 level changes in the early and late periods after radiofrequency and pulsed field catheter ablation of atrial fibrillation.Frontiers in cardiovascular medicine · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: GDF-15 (growth differentiation factor 15) is a protein from the transforming growth factor β (TGF- Methods: This prospective observational study enrolled 50 patients [median (IQR) age 63 (53; 71) years, 62% males] undergoing PFA and compared them with 50 patients [65 (57; 69) years, 64% males] post-RFCA. Results: In the PFA group, 30 (60%) patients had paroxysmal AF, compared with 20 (40%) patients in the RFCA group. The median (IQR) GDF-15 level at baseline was 943 (733; 1,148) ng/L. The median value recorded 24 h after PFA was 1,363 (901; 1,867) ng/L. No significant difference in values was observed between patients treated with RFCA and those treated with PFA. However, when comparing GDF-15 values in paroxysmal AF separately, significantly higher post-procedural GDF-15 levels (immediately post-ablation and in 24 h after procedure) were observed after PFA than RFCA: 963 (672; 1,266) vs. 630 (506; 804) ng/L with Conclusion: GDF-15 levels are significantly affected by catheter ablation of AF, regardless of the ablation technology used.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.